10-K: Lite Strategy Pivots to Litecoin Treasury, Exits Pharma

Lite Strategy, Inc., formerly MEI Pharma, has completed a $100 million PIPE and fully deployed proceeds into a Litecoin Treasury Strategy, marking a significant shift from its pharmaceutical development focus.

Summary

• The company changed its name from MEI Pharma, Inc. to Lite Strategy, Inc. and its ticker symbol to LITS on September 10, 2025.
• The primary business strategy shifted from pharmaceutical development to a Litecoin Treasury Strategy, involving the acquisition of Litecoin (LTC) tokens with the net proceeds from a $100 million Private Investment in Public Equity (PIPE).
• Clinical development of voruciclib was discontinued, and all clinical trial efforts for zandelisib ceased, effectively exiting the pharmaceutical business, though pre-clinical activities for both drug candidates are still being assessed.
• A net loss of $15.9 million was incurred for the fiscal year ended June 30, 2025, a decline from a net income of $17.8 million in fiscal year 2024.
• The accumulated deficit reached $404.2 million as of June 30, 2025.
• Cash and cash equivalents increased to $18.0 million as of June 30, 2025, from $3.7 million in 2024, prior to the deployment of PIPE proceeds.
• Research and development expenses decreased significantly by $12.6 million (76.3%) to $3.9 million for fiscal year 2025 due to the discontinuation of clinical programs.
• General and administrative expenses decreased by $9.8 million (41.9%) to $13.5 million for fiscal year 2025, primarily due to reduced legal/professional fees and corporate overhead, partially offset by $3.6 million in termination benefits.
• A $100.0 million PIPE was closed in July 2025, issuing 23,216,898 common shares at $3.42 per share and pre-funded warrants for 6,022,869 shares at $3.4199 per warrant.
• Warrants for 3,070,177 shares were issued to PIPE advisors with a weighted-average exercise price of approximately $4.10 per share.
• Between July 22 and September 23, 2025, 882,924 common shares were sold through an At-The-Market (ATM) program, generating $4.6 million in net proceeds.
• The Cooperation Agreement with Anson Funds Management LP and Cable Car Capital LLC, which previously resulted in an $11.7 million cash dividend in December 2023, was mutually terminated.
• The merger agreement with Infinity Pharmaceuticals, Inc. was terminated in July 2023 due to a lack of stockholder approval.
• The ME-344 asset was sold for an initial $0.5 million cash payment and potential future milestones up to $62.0 million.

Sentiment

Score: 4

Explanation: The company has made a bold strategic pivot and secured significant capital, which are positive. However, the complete abandonment of its prior business, coupled with the inherent volatility and regulatory uncertainty of its new cryptocurrency focus, introduces substantial risk and makes the future highly unpredictable. The net loss and accumulated deficit also weigh on the sentiment.

Positives

• Successfully raised $100 million in a PIPE offering, significantly bolstering capital for the new strategic direction.
• Implemented a new Litecoin Treasury Strategy, diversifying reserves and aligning with emerging financial technologies.
• Potential for future Litecoin mining activities, indicating an expanding strategy in the digital asset space.
• Reduced Research and Development expenses by 76.3% ($12.6 million) and General and Administrative expenses by 41.9% ($9.8 million) in fiscal year 2025, demonstrating effective cash preservation.
• Cash and cash equivalents increased to $18.0 million as of June 30, 2025, prior to the PIPE proceeds deployment, indicating improved liquidity management.
• The appointment of Charles B. Lee, the creator of Litecoin, to the Board brings significant industry expertise and credibility to the new strategy.
• The sale of the ME-344 asset for $0.5 million upfront and potential $62.0 million in milestones provides non-dilutive capital.

Negatives

• Incurred a net loss of $15.9 million in fiscal year 2025, continuing a history of operating losses and accumulating a deficit of $404.2 million.
• Discontinued clinical development for key drug candidates voruciclib and zandelisib, effectively exiting the pharmaceutical business, which was its prior core focus.
• The new Litecoin Treasury Strategy introduces significant uncertainty and high volatility associated with Litecoin and the broader cryptocurrency market.
• The ability to generate a return on investment from Litecoin depends entirely on its price appreciation, as Litecoin does not pay interest.
• Litecoin holdings are less liquid than cash and cash equivalents and do not enjoy the same protections as traditional securities.
• Potential for Litecoin to be reclassified as a security, which could subject the company to the Investment Company Act of 1940 and significant additional regulatory burdens.
• The company's stock options are currently 'underwater,' meaning their exercise price is above the current share price, reducing their value as an incentive for employees.

Risks

• **Litecoin Price Volatility:** The price of Litecoin has been and will likely continue to be highly volatile, potentially resulting in converting Litecoin into cash with a value substantially below the cost of purchase.
• **Litecoin Liquidity:** Litecoin holdings are less liquid than cash and cash equivalents and may not be able to serve as a source of liquidity during times of market instability.
• **Security Breaches/Cyberattacks:** Risk of partial or total loss of Litecoin due to security breaches, cyberattacks, or loss of private keys, which may not be covered by insurance or liability provisions.
• **Regulatory Developments in Crypto:** Uncertainty regarding the application of existing laws and potential new laws/regulations for crypto assets, which could adversely affect Litecoin's price and the company's business.
• **Investment Company Act of 1940:** A determination that Litecoin is a security could lead to the company being defined as an 'investment company' under the 1940 Act, subjecting it to significant regulatory requirements and potentially forcing sales of Litecoin at unattractive prices.
• **Central Bank Digital Currencies (CBDCs):** The introduction of government-issued digital currencies could reduce the need or demand for private-sector cryptocurrencies, including Litecoin.
• **Future Funding Requirements:** The company may need additional funding to resume drug development or expand crypto activities, with no assurance that such capital will be available on acceptable terms or at all.
• **Intellectual Property Protection:** The value of intellectual property for remaining drug candidates is dependent on obtaining and maintaining patent protection and preserving trade secrets, which cannot be guaranteed, and there is a risk of infringing third-party rights.
• **Employee Misconduct:** Risk of employee fraud or other misconduct, including noncompliance with regulatory standards, which could lead to governmental investigations, fines, or lawsuits.
• **System Failures/Cybersecurity:** Internal computer systems and those of third-party contractors are vulnerable to damage from cyberattacks, natural disasters, and other disruptions, potentially causing data loss or operational delays.
• **Key Employee Retention:** Difficulty in attracting and retaining key employees due to business risks, uncertainties related to R&D, available cash resources, and stock price volatility.
• **Economic Conditions:** Negative U.S. and global economic conditions, including inflation and interest rates, may adversely affect funding costs, access to capital markets, and overall business operations.
• **Public Company Compliance Costs:** Laws and regulations affecting public companies may result in increased costs and difficulty in attracting and retaining qualified directors and executive officers.
• **Privacy Issues:** Risks related to collecting and storing sensitive data, including compliance with evolving privacy laws (e.g., GDPR, CCPA) and potential liability from security incidents.
• **Environmental, Health, and Safety Laws:** Failure to comply with environmental, health, and safety laws and regulations could result in fines, penalties, or significant costs.
• **Limitations on Net Operating Losses (NOLs):** The Tax Cuts and Jobs Act and potential ownership changes under Section 382 may limit the company's ability to utilize NOL carryforwards to offset future taxable income.
• **Nasdaq Listing Standards:** Failure to comply with continued listing standards of the Nasdaq Capital Market could lead to delisting, reducing liquidity and market price of common stock.
• **Stock Price Volatility:** The trading price of common stock has been and may continue to be highly volatile due to factors such as Litecoin value, R&D results, and market conditions, potentially leading to class action litigation.
• **Dilution from Future Sales:** Future sales of common stock, including upon exercise of outstanding warrants or options, may depress the market price and cause stockholders to experience dilution.
• **Broad Discretion Over Proceeds:** Management and the Board will have broad discretion over the use of net proceeds from warrant and option exercises, which may not align with investor expectations.
• **Blank Check Preferred Stock:** The authorization to issue blank check preferred stock with potentially senior rights could adversely affect common stockholders and make a change in control more difficult.
• **Anti-Takeover Provisions:** Provisions in the company's certificate of incorporation and bylaws, as well as Delaware law, could discourage unsolicited takeover proposals.
• **Insider Stock Sales:** Sales of stock by executive officers and directors, or the perception of such sales, could adversely affect the stock price.

Future Outlook

The company anticipates conducting further investigational research and development in the next several months for its drug candidate pipeline. It also plans to initiate an expanding strategy that could include Litecoin mining activities, alongside its commitment to long-term innovation in capital structure and financial technology.

Management Comments

• We believe this strategy will allow us to diversify reserves, enhance capital efficiency and align with emerging financial technologies. (Regarding Litecoin Treasury Strategy)
• We expect our current unrestricted cash and cash equivalents will be sufficient to fund our currently anticipated operating plan for at least the next 12 months.
• We intend to monitor our assets and income in order to conduct our business activities in a manner such that we do not fall within the definition of investment company under the 1940 Act or would qualify under one of the exemptions or exclusions provided by the 1940 Act and corresponding SEC rules.
• The Committee viewed preserving the Company’s cash as the most important metric for measuring Mr. File’s success as it directly benefited shareholders in the event that the strategic review had resulted in liquidation of the Company. (Regarding CEO compensation)

Industry Context

Lite Strategy's pivot from oncology drug development to a Litecoin Treasury Strategy represents a dramatic shift, moving from the highly regulated and capital-intensive pharmaceutical industry to the nascent and volatile digital asset sector. This move contrasts sharply with traditional biotech companies that focus on clinical milestones and regulatory approvals. The entry into cryptocurrency aligns with a broader trend of some companies exploring digital assets for treasury management, but it also exposes the company to the unique risks and regulatory uncertainties of the crypto market, which is still evolving and subject to significant price fluctuations, unlike the more stable, albeit competitive, pharmaceutical market.

Comparison to Industry Standards

• The company's shift from pharmaceutical development to a Litecoin Treasury Strategy is a significant departure from industry standards for publicly traded pharmaceutical or biotechnology companies.
• In the pharmaceutical industry, companies like Pfizer, Johnson & Johnson, or smaller biotechs like Gilead Sciences (which acquired YM Biosciences, a former company of Dr. Glover) typically focus on R&D pipelines, clinical trial success, and regulatory approvals. Lite Strategy has discontinued its clinical programs, effectively exiting this traditional business model.
• The adoption of a Litecoin Treasury Strategy places the company in a new, less defined industry segment, comparable to companies like MicroStrategy, which has adopted Bitcoin as a primary treasury reserve asset. However, Lite Strategy is using Litecoin, a different cryptocurrency, and is also exploring mining activities, which MicroStrategy does not directly engage in.
• The financial performance, including a net loss of $15.9 million and an accumulated deficit of $404.2 million, is not uncommon for clinical-stage biotech companies, but the strategic pivot makes direct comparison to its former biotech peers less relevant.
• The volatility of Litecoin (traded between $50.43 and $146.61 in the 12 months to July 3, 2025) is a standard characteristic of the cryptocurrency market, similar to Bitcoin's volatility, and is a key risk factor for companies holding digital assets.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently party to any material legal proceedings that are expected to have a material adverse effect on business or financial conditions.

Related Party Transactions

• The Cooperation Agreement with Anson Funds Management LP and Cable Car Capital LLC was a related party transaction, which was mutually terminated effective July 22, 2025.
• Entered into a Side Letter with GSR Strategies LLC, a Purchaser in the PIPE, which granted GSR the right to nominate one person to the Board (Joshua Riezman was appointed).
• Entered into an Advisory Agreement with Green Dragon Investments LLC, where Charlie Lee (a newly appointed director) is a beneficiary. Green Dragon provides asset management services and receives fees in warrants.

Stakeholder Impact

• **Shareholders:** Significant strategic shift from biotech to crypto introduces a new, high-risk/high-reward profile. Potential for dilution from future equity raises. The $1.75/share dividend in 2023 provided a capital return.
• **Employees:** A reduction-in-force commenced in August 2024, leading to job terminations and associated benefits. Remaining employees are focused on the new strategy and pre-clinical drug assessment.
• **Customers (former biotech):** Discontinuation of clinical programs means no new drug candidates will be brought to market by Lite Strategy.
• **Suppliers/Partners (former biotech):** Termination of agreements like the KKC Commercialization Agreement and BeiGene collaboration impacts former partners.
• **New Crypto Partners (GSR, Green Dragon, BitGo Prime):** New relationships established for the Litecoin Treasury Strategy, indicating a shift in key business relationships and dependencies.

Next Steps

• Conduct further investigational research and development for pre-clinical drug candidates (voruciclib and zandelisib).
• Initiate an expanding strategy that could include Litecoin mining activities.
• Continue long-term innovation in capital structure and financial technology.
• Monitor assets and income to avoid being classified as an investment company under the 1940 Act.
• Potentially seek additional funding through equity offerings, debt financings, or strategic partnerships.

Key Dates

Recommendation

The company has undergone a radical strategic transformation, exiting its traditional pharmaceutical business to embrace a highly speculative cryptocurrency treasury strategy. While the successful $100 million PIPE offering provides a significant capital injection and the appointment of Litecoin's creator to the board adds credibility to the new direction, the inherent volatility and regulatory uncertainty of digital assets introduce substantial risk. The discontinuation of drug development eliminates the previous growth drivers, and the success of the new strategy is entirely dependent on the appreciation of Litecoin and the company's ability to navigate the complex crypto landscape. Given the extreme shift and the high-risk, high-reward nature of the new business, a 'hold' recommendation is appropriate for investors to observe the execution of the Litecoin Treasury Strategy and the evolving regulatory environment before making further investment decisions. The current 'underwater' options also suggest a lack of immediate upside for existing equity incentives.

Keywords

Litecoin Treasury Strategy, Cryptocurrency, Digital Assets, Strategic Shift, Capital Raise, SEC Filing, 10-K, Financial Reporting, LITS, MEI Pharma, Oncology, Biotechnology, Risk Management